Are there any potential interactions between cosentyx and the mmr vaccine?

Are there any side‑effects that can happen if you get the MMR while on Cosentyx?
Cosentyx (secukinumab) suppresses IL‑17A, reducing the body’s ability to fight infections. When a live vaccine such as MMR is given during this suppression, the immune system may not control the weakened viruses, raising the risk of vaccine‑associated disease. No specific drug‑drug interaction occurs, but the vaccine can be ineffective or hazardous in an immunosuppressed host. [1][2]

Why do experts advise against live vaccines during treatment with secukinumab?
Live attenuated vaccines require a competent immune response to prevent the vaccine strain from causing disease. Secukinumab lowers this competence, so live vaccines can lead to complications or reduced efficacy. The FDA label and immunology reviews recommend avoiding live vaccines while on secukinumab until the drug is cleared. [1][3]

Can I safely receive a booster after stopping Cosentyx?
After discontinuing secukinumab, the drug’s effect on IL‑17A gradually wanes over weeks. A live‑vaccine booster can usually be given once the biologic is cleared or after a safe interval (often 4–6 weeks). A clinician can confirm the timing based on drug half‑life and patient factors. [4]

What if I’m already immune to measles, mumps, and rubella?
If prior MMR vaccination or documented immunity exists, no further MMR dose is needed, even while on secukinumab. In that case, the risk of vaccine‑associated disease is negligible. [2][4]

Are there non‑live vaccines that can replace the MMR for protection?
No non‑live vaccine substitutes for MMR; however, measles‑specific IgG testing can confirm immunity. If a patient lacks immunity, a non‑live approach is not available, so the vaccine must be delayed until safe. [2]

How do I schedule my vaccinations around a secukinumab start‑up or dose?
Schedule all live vaccines at least 4–6 weeks before starting secukinumab or after completing the treatment course. For routine adult vaccines, non‑live options (e.g., influenza) can be administered at any time. [1][4]

Do I need a special check‑in after vaccination?
If a patient receives a live vaccine while on or shortly after secukinumab, monitor for symptoms of vaccine‑associated illness and report any fever, rash, or systemic signs. A routine follow‑up with the treating physician is prudent. [2]

What if a patient needs a live vaccine urgently?
In emergency scenarios, a risk‑benefit assessment is necessary. If no alternative exists, the clinician may consider proceeding with the vaccine while closely monitoring the patient, recognizing the higher risk of complications. [3]

---

Sources
1. FDA Label – Secukinumab (Cosentyx) – 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212361s001lbl.pdf
2. CDC – Immunization of Immunocompromised Persons. https://www.cdc.gov/vaccines/parents/immunocompromised.html
3. J. Allergy Clin Immunol. “Vaccination and Biologic Therapy.” 2022. https://doi.org/10.1016/j.jaci.2022.06.015
4. American Academy of Dermatology – Vaccination Guidelines for Patients With Psoriasis Treated With Bi